Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study

Sridhar Chilimuri, Haozhe Sun, Ahmed Alemam, Kyoung Sil Kang, Peter Lao, Nikhitha Mantri, Lawrence Schiller, Myroslava Sharabun, Elona Shehi, Jairo Tejada, Alla Yugay, Suresh Kumar Nayudu

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

What is known and objective: The coronavirus disease 2019 (COVID-19) associated cytokine activation can lead to a rapid progression into respiratory failure, shock and multiorgan failure. Interleukin-6 (IL-6) is a pro-inflammatory cytokine that likely contributes to the pathogenesis of cytokine release syndrome. It is hypothesized that modulating IL-6 levels or its effects with tocilizumab, a recombinant humanized anti-IL-6 receptor monoclonal antibody, may alter the course of disease. Methods: We examined the association between tocilizumab use and intubation or death at a community hospital in New York City. Data were obtained regarding consecutive patients hospitalized with COVID-19. The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received tocilizumab with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. Results and Discussion: In this single-centre retrospective cohort study involving 1225 hospitalized patients with SARS-CoV-2 infection, the probability to respiratory failure, which was measured as intubation or death, was less frequent in patients who received tocilizumab. What is new and conclusion: Tocilizumab and other IL-6 receptor monoclonal antibodies may evolve as a viable option in treating patients with moderate and severe COVID-19.

Original languageEnglish
Pages (from-to)440-446
Number of pages7
JournalJournal of Clinical Pharmacy and Therapeutics
Volume46
Issue number2
DOIs
StatePublished - Apr 2021

Keywords

  • COVID-19
  • SARS-CoV-2
  • coronavirus
  • cytokine release syndrome
  • interleukin-6
  • tocilizumab

Fingerprint

Dive into the research topics of 'Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study'. Together they form a unique fingerprint.

Cite this